The aim of the Small Molecule Pharmaceutical Development process is to design a safe, quality product that delivers a therapeutic benefit to patients. All major chemical domains need to work in close concert to develop a molecule into a drug product which is ready for the market. In this presentation, selected chemical aspects of SMPD including synthesis route scouting, analytical development, formulation studies, process research and engineering will be presented.
Guido Verniest obtained his PhD from Ghent University working in the group of Norbert De Kimpe in 2004 and continued in that group as a FWO postdoc. He performed a postdoc in the lab of Albert Padwa at Emory University from 2007-2008. He was appointed as lecturer at Vrije Universiteit Brussel in 2010. After 8 years at VUB, he joined Janssen working on Forced degradation of API’s and moved internally to the Discovery Process Research group in 2019 where he currently works on the development of new synthesis pathways to enable medicinal chemistry and to facilitate the transition of synthetic procedures to larger scale processes.